48 related articles for article (PubMed ID: 15703014)
1. High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy.
Gladstone DE; Prestrud AA; Brannagan TH
J Peripher Nerv Syst; 2005 Mar; 10(1):11-6. PubMed ID: 15703014
[TBL] [Abstract][Full Text] [Related]
2. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial.
Hughes R; Dalakas MC; Merkies I; Latov N; Léger JM; Nobile-Orazio E; Sobue G; Genge A; Cornblath D; Merschhemke M; Ervin CM; Agoropoulou C; Hartung HP;
Lancet Neurol; 2018 Aug; 17(8):689-698. PubMed ID: 30001923
[TBL] [Abstract][Full Text] [Related]
3. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy.
Good JL; Chehrenama M; Mayer RF; Koski CL
Neurology; 1998 Dec; 51(6):1735-8. PubMed ID: 9855536
[TBL] [Abstract][Full Text] [Related]
4. Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders.
Chiang JCB; Arnold R; Dhanapalaratnam R; Markoulli M; Krishnan AV
Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631433
[TBL] [Abstract][Full Text] [Related]
5. Progress in Hematopoietic Stem Cell Transplantation for CIDP.
Qin Z; Huang Q; Zou J; Tang L; Hu Z; Tang X
Int J Med Sci; 2020; 17(2):234-241. PubMed ID: 32038107
[TBL] [Abstract][Full Text] [Related]
6. Immune-mediated neuropathies.
Kieseier BC; Mathey EK; Sommer C; Hartung HP
Nat Rev Dis Primers; 2018 Oct; 4(1):31. PubMed ID: 30310069
[TBL] [Abstract][Full Text] [Related]
7. Severe refractory CIDP: a case series of 10 patients treated with bortezomib.
Pitarokoili K; Yoon MS; Kröger I; Reinacher-Schick A; Gold R; Schneider-Gold C
J Neurol; 2017 Sep; 264(9):2010-2020. PubMed ID: 28836002
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.
Mahdi-Rogers M; Brassington R; Gunn AA; van Doorn PA; Hughes RA
Cochrane Database Syst Rev; 2017 May; 5(5):CD003280. PubMed ID: 28481421
[TBL] [Abstract][Full Text] [Related]
9. Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment.
Ellrichmann G; Gold R; Ayzenberg I; Yoon MS; Schneider-Gold C
Ther Adv Neurol Disord; 2017 Feb; 10(2):91-101. PubMed ID: 28382108
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic inflammatory demyelinating polyneuropathy.
Kleyman I; Brannagan TH
Curr Neurol Neurosci Rep; 2015 Jul; 15(7):47. PubMed ID: 26008811
[TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations.
Ripellino P; Fleetwood T; Cantello R; Comi C
Autoimmune Dis; 2014; 2014():201657. PubMed ID: 24527207
[TBL] [Abstract][Full Text] [Related]
12. Multifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, and other chronic acquired demyelinating polyneuropathy variants.
Dimachkie MM; Barohn RJ; Katz J
Neurol Clin; 2013 May; 31(2):533-55. PubMed ID: 23642723
[TBL] [Abstract][Full Text] [Related]
13. Chronic inflammatory demyelinating polyneuropathy.
Dimachkie MM; Barohn RJ
Curr Treat Options Neurol; 2013 Jun; 15(3):350-66. PubMed ID: 23564314
[TBL] [Abstract][Full Text] [Related]
14. Advances in the diagnosis, pathogenesis and treatment of CIDP.
Dalakas MC;
Nat Rev Neurol; 2011 Aug; 7(9):507-17. PubMed ID: 21844897
[TBL] [Abstract][Full Text] [Related]
15. Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy.
Yoon MS; Chan A; Gold R
Ther Adv Neurol Disord; 2011 May; 4(3):193-200. PubMed ID: 21694819
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory demyelinating neuropathies.
Lopate G; Pestronk A
Curr Treat Options Neurol; 2011 Apr; 13(2):131-42. PubMed ID: 21243541
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis and treatment of immune-mediated neuropathies.
Lehmann HC; Meyer Zu Horste G; Kieseier BC; Hartung HP
Ther Adv Neurol Disord; 2009 Jul; 2(4):261-81. PubMed ID: 21179533
[TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy and multiple sclerosis.
Harrison D; Gladstone DE
Curr Opin Oncol; 2011 Mar; 23(2):221-6. PubMed ID: 21169833
[TBL] [Abstract][Full Text] [Related]
19. Treatment of chronic inflammatory demyelinating polyneuropathy.
Robertson EE; Donofrio PD
Curr Treat Options Neurol; 2010 Mar; 12(2):84-94. PubMed ID: 20842572
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
